Morning Trend | HAIXI PHARMA fluctuates at a high level, is the pharmaceutical leading sector under pressure?

HAIXI PHARMA (2637.HK) has recently been fluctuating at a high stage, with funds attempting to push up but lacking strength, indicating a divergence in the willingness of main funds. The pharmaceutical sector has been continuously undergoing valuation repair this year, with leading companies in the sector attracting institutions to increase their allocations due to their defensive attributes. Recently, mainstream companies have intensively released quarterly performance pre-increase announcements, triggering a simultaneous strengthening of second-tier varieties in the pharmaceutical branch concept. However, leading stocks like HAIXI PHARMA are not cooperating with increased volume at high price ranges, and the divergence between volume and price is becoming more pronounced